Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.11. | CAMP4 Analyst Highlights Rare Disease Platform Potential | 2 | Benzinga.com | ||
CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
05.11. | Camp4 gains after earning bullish views on Street | 1 | Seeking Alpha | ||
05.11. | William Blair upbeat on CAMP4 shares with Outperform rating | 3 | Investing.com | ||
05.11. | Leerink sets stock target for CAMP4, cites broad UCD treatment potential | 1 | Investing.com | ||
05.11. | Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology | 1 | Investing.com | ||
05.11. | Piper Sandler optimistisch für CAMP4-Aktie, verweist auf Potenzial in bahnbrechender RNA-Technologie | 1 | Investing.com Deutsch | ||
05.11. | JPMorgan sees "breakthrough potential" in CAMP4 stock, bets big on RNA tech | 4 | Investing.com | ||
16.10. | Camp4 Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
15.10. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
11.10. | CAMP4 stock edges up 2% following $75M IPO | 5 | Seeking Alpha | ||
11.10. | RNA biotech CAMP4 Therapeutics prices IPO below the range at $11; adds shares to keep deal size at $75 million | 2 | Renaissance Capital | ||
11.10. | CAMP4 Therapeutics prices $75MIPO at $11 per share | 1 | Seeking Alpha | ||
11.10. | CAMP4 Therapeutics Prices 6.82M Share IPO at $11/sh | 2 | Investing.com | ||
11.10. | Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4 | 1 | FierceBiotech | ||
11.10. | CAMP4 Therapeutics: CAMP4 Announces Pricing of Initial Public Offering | 95 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting... ► Artikel lesen | |
08.10. | Upstream Bio, CeriBell, CAMP4 set terms for proposed IPOs | 1 | Seeking Alpha | ||
08.10. | Camp4 Therapeutics Corp - 8-A12B, Registration of securities | 1 | SEC Filings | ||
07.10. | CAMP4 is latest biotech to eye IPO, while Upstream spells out $182M plans | 3 | FierceBiotech | ||
07.10. | Genetic disease biotech CAMP4 Therapeutics sets terms for $75 million IPO | 1 | Renaissance Capital | ||
07.10. | CAMP4 Therapeutics Announces 5M Share IPO at $14-$16/sh | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AVIDITY BIOSCIENCES | 52,55 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
QIAGEN | 40,430 | +0,56 % | DAX-Check LIVE: Daimler Truck, Delivery Hero, Heidelberg, Lanxess, Munich Re, Nordex, Qiagen & Co. | Nachdem gestern feststand, dass Donald Trump die US-Wahl für sich entschieden hat, stieg der DAX zunächst um rund 1,5 Prozent an. Doch dann trat schnell Ernüchterung ein. Am Ende gab der DAX 1,13 Prozent... ► Artikel lesen | |
DYNE THERAPEUTICS | 34,150 | 0,00 % | Dyne Therapeutics GAAP EPS of -$0.96 misses by $0.25 | ||
EVOTEC | 8,575 | +0,12 % | TUI, Evotec, BioNxt Solutions: SHORT SQUEEZE, KURSDEBAKEL und MOMENTUM AKTIE | 50 % hat die Aktie von BioNxt Solutions seit Ende August zulegen können. Die Chancen stehen gut, dass das Momentum bei dem Biotech-Unternehmen anhält. Denn allein um das Niveau von Januar zu erreichen... ► Artikel lesen | |
NUVALENT | 90,27 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results | Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product... ► Artikel lesen | |
ARS PHARMACEUTICALS | 14,060 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 34,590 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,310 | 0,00 % | Recursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed Combination | Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated closeSalt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq:... ► Artikel lesen | |
BIONTECH | 106,40 | +0,76 % | Biontech sitzt auf riesigem Finanzpolster | Im abgelaufenen Quartal wartet Biontech mit einem Umsatzsprung auf und schreibt schwarze Zahlen. Für das Gesamtjahr sieht es dagegen nicht ganz so gut aus. Die finanzielle Ausstattung stimmt wiederum.... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 19,470 | 0,00 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,77 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
LEXEO THERAPEUTICS | 7,750 | 0,00 % | Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results | Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression... ► Artikel lesen | |
ADMA BIOLOGICS | 21,470 | 0,00 % | ADMA Biologics-Aktie erreicht Allzeithoch von 21,25 US-Dollar | ||
89BIO | 8,920 | 0,00 % | 89bio slips after $125 million stock deal | ||
PHATHOM PHARMACEUTICALS | 9,740 | 0,00 % | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report |